ClinicalTrials.gg
CompletedNCT03368118Updated May 29, 2025Results posted

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

A Phase 2 interventional study of ABX464 in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies in Colitis, Ulcerative with a site in Belgium — 26 open to participants now, 50 under way, 27 of them phase 3. Colitis, Ulcerative · Belgium.

Enrollment
163rd of 168
22 · median 198
Started
2018
with 16 others
Phase 2
59 of 187
4 open now
Registered
98th of 187
by date
Lead sponsor
8 of 187
Abivax S.A.

Among the 187 studies in Colitis, Ulcerative with a site in Belgium, this one is the 163rd largest by enrollment of the 168 interventional ones that give a count, is one of 17 that started in 2018, is one of 59 in phase 2, and was the 98th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

26 of the 187 studies in Colitis, Ulcerative with a site in Belgium are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Colitis, Ulcerative with a site in Belgium, or all of them as a file.
02

Study summary

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue their treatment.

Read the detailed description

This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue their treatment.

All subjects will receive ABX464 given at 50 mg o.d irrespective of their previous treatment received in the ABX464-101 study (i.e. ABX464 or Placebo).

The actual treatment received by a subject throughout the previous study (ABX464-101) will not be known at the time the subjects enter this follow-up study. This treatment group will be communicated (throughout the investigators) to the subjects at the end of the ABX464-101 study (planned in Q3/2018).

The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation and also based on investigator's judgement.

Subjects will be treated with ABX464 for an overall period of 48 months. Subjects will be followed up weekly during the first month, every two weeks during the second month and then on a monthly basis until M24, then quaterly from M24 to M48.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • ABX464
  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for inclusion in this study only if ALL of the following criteria apply:

  • Subjects previously enrolled in the ABX464-101 clinical study who have completed the initial 2-month treatment phase;
  • Subjects able and willing to comply with study visits and procedures;
  • Subjects with hematological and biochemical laboratory parameters as follows at the D56 visit of the ABX464-101 study:

    • > 9.0 g dL-1;
    • ≥ 750 mm-3;
    • ≥ 100,000 mm-3;
    • Total serum creatinine ≤ 1.3 x (upper limit of normal);
    • > 50 mL min-1 by the Cockcroft-Gault equation;
    • Total serum \< 1.5 x ULN;
    • Alkaline phosphatase, (SGOT) and ALT (SGPT) \< 1.5 x ULN;
  • Subjects should understand, sign and date the written voluntary form at the enrolment visit prior to any protocol-specific procedures being performed;
  • Subjects should be affiliated to a social security regimen (for French sites only);
  • Females and males receiving the study treatment and their partners must agree to use a highly effective method during the study and for 3 months after end of study or early termination. Contraception should be in place at least 3 months prior to study participation. Women must be either (at least 12 months of amenorrhea), surgically sterile or if of must use a highly effective contraceptive method. Women of childbearing potential (WOCBP) will enter the study after confirmed menstrual period and a negative pregnancy test. Highly effective methods of contraception include: true abstinence, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), hormonal contraception (estrogen and progestogen or progestogen only) associated with inhibition of ovulation, bilateral tubal occlusion, vasectomized partner. True abstinence is defined when this is in line with the preferred and usual lifestyle of the subject. In each case of delayed menstrual period (over one month between menstruations) confirmation of absence of pregnancy is required. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycle.

Exclusion criteria

Exclusion Criteria:

The following criterion should be checked at the time of screening. If this exclusion criterion applies, the subject will not be included in the study:

▪ Any condition, which in the opinion of the investigator, could compromise the subject's safety or the adherence to the study protocol.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    ABX464 Treatment arm

    All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.

    Drug: ABX464

Interventions

  • DrugABX464

    All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.

06

What researchers measure

Primary outcomes

  1. Number of Treatment-emergent Adverse Events

    Number of treatment-emergent adverse events in ABX464 treated subjects

    Time frame: Through subject study treatment, up to 48 months

Secondary outcomes

  1. Total Mayo Score

    The change from Day 0 up to Month 48 in Total Mayo Score. total mayo score is an index and consists of 4 items: stool frequency, rectal bleeding, flexible sigmoidoscopic examination, and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The total mayo score scale ranging is from 0 to 12 The change from baseline of this score is part of the clinical response definition: to get a clinical response, a reduction in Total Mayo score of at least 2 points is required. A higher (in negative) change shows a better clinical response.

    Time frame: Up to Month 48

  2. Partial Mayo Score

    The change from Day 0 up to Month 48 in Partial Mayo Score; Partial Mayo score is an index and consists of 3 items: stool frequency, rectal bleeding and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The partial mayo score scale ranging is from 0 to 9. A higher (in negative) change from baseline shows a better clinical response

    Time frame: Up to Month 48

  3. Number of Subjects With Clinical Response at Month 48

    Clinical response was defined as: reduction in Total Mayo Score (TMS) of at least 2 points and \>= 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of \>= 1 point or absolute rectal bleeding sub-score of \<= 1 point.

    Time frame: up to 48 months

  4. Number of Subjects With Clinical Remission at Month 48

    Clinical remission was achieved when all the following criteria were met in the components of the Mayo clinical Score: rectal bleeding sub-score = 0 central endoscopy sub-score \<= 1 stool frequency sub-score \<= 1

    Time frame: up to 48 months

  5. Number of Subject With Endoscopic Improvement at Month 48

    oEndoscopic improvement was achieved if the Mayo central endoscopic sub-score is 0 or 1.

    Time frame: up to 48 Months

  6. Number of Subjects With Endoscopic Remission at Month 48

    Endoscopic remission was defined as Mayo central endoscopic sub-score = 0

    Time frame: up to 48 months

  7. Fecal Calprotectin

    The change from Day 0 up to Month 48 in fecal calprotectin A higher (in negative) change shows a better efficacy

    Time frame: Up to Month 48

  8. CRP Levels

    The change from Day 0 up to Month 48 in CRP levels

    Time frame: Up to Month 48

  9. Number of Treatment-emergent Serious Adverse Events

    The number of incidences of treatment-emergent serious adverse events

    Time frame: Through subject study treatment, up to 48 months

  10. Number of Treatment-emergent Adverse Events of Special Interest

    The number of incidences of treatment-emergent adverse events of special interest

    Time frame: Through subject study treatment, up to 48 months

  11. Number of Adverse Events Leading to Investigational Product Discontinuation

    The number of incidences of adverse events leading to investigational product discontinuation

    Time frame: Through subject study treatment, up to 48 months

  12. Number of Specific Laboratory Abnormalities

    The number of incidences of specific laboratory abnormalities

    Time frame: Through first year of subject study treatment, 12 months

  13. SF-36 Quality of Life Questionnaire (SF-36 Physical Component)

    Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 physical component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement

    Time frame: Up to 24 months

  14. SF-36 Quality of Life Questionnaire (SF-36 Mental Component)

    Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 mental component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement

    Time frame: Up to 24 months

  15. Erythrocyte Sedimentation Rate (ESR) Levels

    The change from Day 0 up to Month 48 in ESR levels

    Time frame: up to 48 Months

07

Results

Posted Mar 5, 2025

Participant flow

Participant flow — Overall Study
MilestoneABX464 Treatment Arm
Started22
Completed11
Not completed11

Outcome measures

PrimaryNumber of Treatment-emergent Adverse Events

Number of treatment-emergent adverse events in ABX464 treated subjects

Time frame:
Through subject study treatment, up to 48 months
Reported as:
Number · events
Number of Treatment-emergent Adverse Events
eventsABX464 Treatment Arm
Number of Treatment-emergent Adverse Events145
SecondaryTotal Mayo Score

The change from Day 0 up to Month 48 in Total Mayo Score. total mayo score is an index and consists of 4 items: stool frequency, rectal bleeding, flexible sigmoidoscopic examination, and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The total mayo score scale ranging is from 0 to 12 The change from baseline of this score is part of the clinical response definition: to get a clinical response, a reduction in Total Mayo score of at least 2 points is required. A higher (in negative) change shows a better clinical response.

Time frame:
Up to Month 48
Reported as:
Mean · units on a scale
Total Mayo Score
units on a scaleABX464 Treatment Arm
Total Mayo Score-3.0 ± 3.4
SecondaryPartial Mayo Score

The change from Day 0 up to Month 48 in Partial Mayo Score; Partial Mayo score is an index and consists of 3 items: stool frequency, rectal bleeding and a physician global assessment of disease activity. Each parameter of the score ranges from zero (normal or inactive disease) to 3 (severe activity). The partial mayo score scale ranging is from 0 to 9. A higher (in negative) change from baseline shows a better clinical response

Time frame:
Up to Month 48
Reported as:
Mean · units on a scale
Partial Mayo Score
units on a scaleABX464 Treatment Arm
Partial Mayo Score-2.2 ± 2.4
SecondaryNumber of Subjects With Clinical Response at Month 48

Clinical response was defined as: reduction in Total Mayo Score (TMS) of at least 2 points and \>= 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of \>= 1 point or absolute rectal bleeding sub-score of \<= 1 point.

Time frame:
up to 48 months
Reported as:
Count of participants · Participants
Number of Subjects With Clinical Response at Month 48
ParticipantsABX464 Treatment Arm
Number of Subjects With Clinical Response at Month 4811
SecondaryNumber of Subjects With Clinical Remission at Month 48

Clinical remission was achieved when all the following criteria were met in the components of the Mayo clinical Score: rectal bleeding sub-score = 0 central endoscopy sub-score \<= 1 stool frequency sub-score \<= 1

Time frame:
up to 48 months
Reported as:
Count of participants · Participants
Number of Subjects With Clinical Remission at Month 48
ParticipantsABX464 Treatment Arm
Number of Subjects With Clinical Remission at Month 489
SecondaryNumber of Subject With Endoscopic Improvement at Month 48

oEndoscopic improvement was achieved if the Mayo central endoscopic sub-score is 0 or 1.

Time frame:
up to 48 Months
Reported as:
Count of participants · Participants
Number of Subject With Endoscopic Improvement at Month 48
ParticipantsABX464 Treatment Arm
Number of Subject With Endoscopic Improvement at Month 489
SecondaryNumber of Subjects With Endoscopic Remission at Month 48

Endoscopic remission was defined as Mayo central endoscopic sub-score = 0

Time frame:
up to 48 months
Reported as:
Count of participants · Participants
Number of Subjects With Endoscopic Remission at Month 48
ParticipantsABX464 Treatment Arm
Number of Subjects With Endoscopic Remission at Month 486
SecondaryFecal Calprotectin

The change from Day 0 up to Month 48 in fecal calprotectin A higher (in negative) change shows a better efficacy

Time frame:
Up to Month 48
Reported as:
Mean · ug/g
Fecal Calprotectin
ug/gABX464 Treatment Arm
Fecal Calprotectin-299.69 ± 472.28
SecondaryCRP Levels

The change from Day 0 up to Month 48 in CRP levels

Time frame:
Up to Month 48
Reported as:
Mean · mg/L
CRP Levels
mg/LABX464 Treatment Arm
CRP Levels2.29 ± 4.82
SecondaryNumber of Treatment-emergent Serious Adverse Events

The number of incidences of treatment-emergent serious adverse events

Time frame:
Through subject study treatment, up to 48 months
Reported as:
Number · events
Number of Treatment-emergent Serious Adverse Events
eventsABX464 Treatment Arm
Number of Treatment-emergent Serious Adverse Events3
SecondaryNumber of Treatment-emergent Adverse Events of Special Interest

The number of incidences of treatment-emergent adverse events of special interest

Time frame:
Through subject study treatment, up to 48 months
Reported as:
Number · events
Number of Treatment-emergent Adverse Events of Special Interest
eventsABX464 Treatment Arm
Number of Treatment-emergent Adverse Events of Special Interest15
SecondaryNumber of Adverse Events Leading to Investigational Product Discontinuation

The number of incidences of adverse events leading to investigational product discontinuation

Time frame:
Through subject study treatment, up to 48 months
Reported as:
Number · event
Number of Adverse Events Leading to Investigational Product Discontinuation
eventABX464 Treatment Arm
Number of Adverse Events Leading to Investigational Product Discontinuation1
SecondaryNumber of Specific Laboratory Abnormalities

The number of incidences of specific laboratory abnormalities

Time frame:
Through first year of subject study treatment, 12 months
Reported as:
Number · events
Number of Specific Laboratory Abnormalities
eventsABX464 Treatment Arm
Number of Specific Laboratory Abnormalities17
SecondarySF-36 Quality of Life Questionnaire (SF-36 Physical Component)

Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 physical component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement

Time frame:
Up to 24 months
Reported as:
Mean · units on a scale
SF-36 Quality of Life Questionnaire (SF-36 Physical Component)
units on a scaleABX464 Treatment Arm
SF-36 Quality of Life Questionnaire (SF-36 Physical Component)4.82 ± 4.23
SecondarySF-36 Quality of Life Questionnaire (SF-36 Mental Component)

Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health on eight multi-item dimensions, covering functional status, well-being, and overall evaluation of health. These items are grouped in 2 distincts components: a physical component (SF-36 physical) and a mental component (SF-36 mental). This outcome describes the SF-36 mental component. Each item score ranging is from 0 to 100. A higher positive value in change indicate a better health status. The higher the change from baseline, the better improvement

Time frame:
Up to 24 months
Reported as:
Mean · units on a scale
SF-36 Quality of Life Questionnaire (SF-36 Mental Component)
units on a scaleABX464 Treatment Arm
SF-36 Quality of Life Questionnaire (SF-36 Mental Component)6.38 ± 3.40
SecondaryErythrocyte Sedimentation Rate (ESR) Levels

The change from Day 0 up to Month 48 in ESR levels

Time frame:
up to 48 Months
Reported as:
Mean · mm/hour
Erythrocyte Sedimentation Rate (ESR) Levels
mm/hourABX464 Treatment Arm
Erythrocyte Sedimentation Rate (ESR) Levels2.90 ± 8.62
Post-hocUC Worsening

Proportion of subjects with UC worsening based on adverse events

Time frame:
Up to Month 48
Reported as:
Count of participants · Participants
UC Worsening
ParticipantsABX464 Treatment Arm
UC Worsening7

Adverse events

Collected over Adverse event were collected from first day of dosing (baseline) up to last safety visit (up to 49 months : 48 months on treatment and one month safety follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX464 Treatment Arm0/22 (0%)3/22 (13.6%)20/22 (90.9%)
Most frequent serious events
Most frequent serious events
EventABX464 Treatment Arm
Myocardial infarctionCardiac disorders1/22
enteropathic spondylitisMusculoskeletal and connective tissue disorders1/22
benign ovarian tumorNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/22
Most frequent other events
Showing 10 of 13
Most frequent other events
EventABX464 Treatment Arm
colitis ulcerativeGastrointestinal disorders7/22
Abdominal painGastrointestinal disorders5/22
nasopharyngitisInfections and infestations5/22
diarrhoeaGastrointestinal disorders4/22
vomitingGastrointestinal disorders3/22
headacheNervous system disorders3/22
Abdominal pain upperGastrointestinal disorders2/22
DyspepsiaGastrointestinal disorders2/22
nauseaGastrointestinal disorders2/22
PyrexiaGeneral disorders2/22

Baseline characteristics

Age, Continuous
Age, Continuous(years)ABX464 Treatment Arm
Mean42.4 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)ABX464 Treatment Arm
Female9
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABX464 Treatment Arm
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White22
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)ABX464 Treatment Arm
Belgium3
Poland10
Hungary9
08

Study locations

1 site
  • Department of Gastroenterology - University hospitals Leuven
    Leuven, 3000, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jul 2022, 53 months.

Results were first posted in Mar 2025, 2 years 7 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 53 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Dec 11, 2017
StartActual
Jan 20, 2018
Primary completionActual
Jul 12, 2022
CompletionActual
Aug 15, 2022
Results first posted
Mar 5, 2025
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03368118
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Dec 11, 2017
Start date
Jan 20, 2018
Primary completion
Jul 12, 2022
Completion
Aug 15, 2022
Results posted
Mar 5, 2025
Last update
May 29, 2025

Study contacts

Paul GINESTE
study director · Abivax S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion